Summary:
- This article discusses the results of a Phase 2 clinical trial for a new drug called REGN-COV2, which is being developed by the pharmaceutical company Regeneron.
- The trial showed that REGN-COV2 was effective in reducing the viral load and improving the symptoms of COVID-19 patients, especially those who had not developed their own antibodies against the virus.
- The positive results from this trial suggest that REGN-COV2 could be a promising treatment option for COVID-19, and the drug is now moving on to larger Phase 3 trials to further evaluate its safety and efficacy.